Heron is running out of money

Quote

anonymous

Guest
The company ended last year with $131 million in cash. It's management's opinion that this is sufficient to keep the company's operations funded through the end of the year, including a potential commercial launch of Sustol. To me, that seems awfully light. That was when they believed Sustol would be launched in January.........it has been delayed 3 times this year and the money is running out......
 






They cancelled company meeting this week, that will save a few $'s. We are not getting any bonuses since the drug has not come to market yet......best paid vacation I have ever had in my career! I am not complaining but actively looking....this company will not last with out any money coming in......
 






"Our NDA for SUSTOL is pending review with the FDA and was assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of January 17, 2016. In January 2016, we were notified by the FDA that it would not take action on the SUSTOL NDA by the PDUFA goal date and that the FDA anticipates taking action on the SUSTOL NDA in late February 2016." It is now late April.....what is the hold up with the FDA?
 












anonymous said:
Wow enlightening, that means they are spending 11 million a month with no return on their investment.....this company will go belly up in no time.....
Click to expand...

Things are just fine. Let's calm down all the "belly up" talk.
Boy somebody sure has some emotional investment in this company not doing well. Let's see who do we know that has a reason to be upset??
 
























Heron reported a loss of $33.4 million in its first quarter.

On a per-share basis, the Redwood City, California-based company said it had a loss of 92 cents.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 98 cents per share.

Heron Therapeutics shares have declined 30 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $18.66, an increase of 68 percent in the last 12 months. Down today to $ 16.36.
 




































Net income of -33.45 million this period compared to a net income of -31.24 million last period. This is a growth of -7.05% over the previous period. How much longer can they survive?
 












anonymous said:
Don't kid yourselves, with an uncertain approval, time to cut the commercial team.
Click to expand...


Great plan. Cut the trained and easy to go commercial team because your uncertain when the approval will come.

kinda like how I deploy the airbag in my car ahead of time because I'm just not sure when the crash will come.

If the approval doesn't come you cut the team. If you don't know and you've invested this much and are this close to an answer you don't start tossing people out.

You wait and see what happens.
 
























Top Bottom
Back
Quote